Kaiser Permanente Vallejo Medical Center

Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review

Background/Objectives: Incretin-based therapies, including glucagon like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, are increasingly prescribed for obesity, leading to greater recognition of associated dermatological...

Adipocytes as a Mechanistic Link Between Incretin-Based Therapies and Hair Loss

The physiological effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs extend beyond glucose metabolism and body weight regulation. Accumulating clinical evidence has highlighted an association betwee...